• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Central Nervous System Pseudoprogression With Nivolumab in a Patient With Squamous Cell Lung Cancer Followed by Prolonged Response.

作者信息

Swami Umang, Smith Mark, Zhang Jun

机构信息

Division of Hematology, Oncology and Blood & Marrow Transplantation, Department of Internal Medicine, Holden Comprehensive Cancer Center, University of Iowa Carver College of Medicine, Iowa City, Iowa.

Department of Radiation Oncology, Holden Comprehensive Cancer Center, University of Iowa Carver College of Medicine, Iowa City, Iowa.

出版信息

J Thorac Oncol. 2018 Sep;13(9):e183-e184. doi: 10.1016/j.jtho.2018.05.001.

DOI:10.1016/j.jtho.2018.05.001
PMID:30166022
Abstract
摘要

相似文献

1
Central Nervous System Pseudoprogression With Nivolumab in a Patient With Squamous Cell Lung Cancer Followed by Prolonged Response.一名鳞状细胞肺癌患者使用纳武利尤单抗后出现中枢神经系统假性进展，随后出现长期缓解。
J Thorac Oncol. 2018 Sep;13(9):e183-e184. doi: 10.1016/j.jtho.2018.05.001.
2
Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy.先前接受纳武利尤单抗单药治疗的非小细胞肺癌患者的假性进展。
J Thorac Oncol. 2019 Mar;14(3):468-474. doi: 10.1016/j.jtho.2018.10.167. Epub 2018 Nov 20.
3
A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab.1例特发性肺纤维化合并肺鳞状细胞癌患者接受纳武单抗治疗的病例
J Thorac Oncol. 2017 Jul;12(7):e96-e97. doi: 10.1016/j.jtho.2017.03.008.
4
Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.抗 PD-1 治疗晚期非小细胞肺癌中的影像学假性进展。
J Thorac Oncol. 2018 Jul;13(7):978-986. doi: 10.1016/j.jtho.2018.04.010. Epub 2018 May 5.
5
Tumor pseudoprogression during nivolumab immunotherapy for lung cancer.纳武单抗免疫治疗肺癌期间的肿瘤假性进展
Radiologia (Engl Ed). 2019 Nov-Dec;61(6):498-505. doi: 10.1016/j.rx.2019.05.004. Epub 2019 Jul 9.
6
Acquired Hemophilia A After Nivolumab Therapy in a Patient With Metastatic Squamous Cell Carcinoma of the Lung Successfully Managed With Rituximab.纳武单抗治疗转移性肺鳞状细胞癌患者后发生获得性血友病A，使用利妥昔单抗成功治疗。
Clin Lung Cancer. 2019 Sep;20(5):e560-e563. doi: 10.1016/j.cllc.2019.06.022. Epub 2019 Jun 26.
7
Mechanism of acquired resistance to nivolumab in lung squamous cell carcinoma: case report and review of the literature.肺鳞癌获得性对纳武利尤单抗耐药的机制：病例报告及文献复习。
Immunotherapy. 2020 Sep;12(13):957-964. doi: 10.2217/imt-2020-0038. Epub 2020 Jul 19.
8
[A Case of Myocardial and Cutaneous Metastases of Squamous Cell Lung Cancer Post Left Pneumonectomy and Radical Surgery for Cutaneous Metastasis during Nivolumab Therapy].[1例肺鳞状细胞癌左肺切除术后发生心肌和皮肤转移及在纳武单抗治疗期间行皮肤转移灶根治性手术的病例]
Gan To Kagaku Ryoho. 2018 Oct;45(10):1441-1444.
9
Atypical response with bone pseudoprogression in a patient receiving nivolumab for advanced cutaneous squamous cell carcinoma.接受纳武利尤单抗治疗的晚期皮肤鳞状细胞癌患者出现骨假性进展的非典型反应。
J Immunother Cancer. 2018 Nov 27;6(1):130. doi: 10.1186/s40425-018-0444-5.
10
Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan.尼伏鲁单抗治疗非小细胞肺癌患者的真实世界疗效和安全性：日本多中心回顾性观察研究。
Lung Cancer. 2020 Feb;140:8-18. doi: 10.1016/j.lungcan.2019.11.014. Epub 2019 Nov 20.

引用本文的文献

1
Immune response evaluation criteria in solid tumors for assessment of atypical responses after immunotherapy.实体瘤免疫反应评估标准，用于评估免疫治疗后的非典型反应。
World J Clin Oncol. 2021 May 24;12(5):323-334. doi: 10.5306/wjco.v12.i5.323.
2
Efficacy and safety of immune checkpoint inhibitors (ICIs) in extensive-stage small cell lung cancer (SCLC).免疫检查点抑制剂（ICI）在广泛期小细胞肺癌（SCLC）中的疗效和安全性。
J Cancer Res Clin Oncol. 2021 Feb;147(2):593-606. doi: 10.1007/s00432-020-03362-z. Epub 2020 Aug 27.
3
The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy.
免疫治疗后肿瘤假性进展的潜在机制、识别及临床意义
Cancer Biol Med. 2019 Nov;16(4):655-670. doi: 10.20892/j.issn.2095-3941.2019.0144.
4
[A Case of Pseudoprogression During Atezolizumab Therapy 
in Lung Adenocarcinoma].[1例肺腺癌阿替利珠单抗治疗期间假性进展的病例]
Zhongguo Fei Ai Za Zhi. 2019 Jun 20;22(6):389-394. doi: 10.3779/j.issn.1009-3419.2019.06.10.